osteoporosis%20in%20women
OSTEOPOROSIS IN WOMEN
Osteoporosis is a progressive, systemic, skeletal disease characterized by decreased bone mass and microarchitectural deterioration of bone tissue leading to increased bone fragility and susceptibility to fractures.
The more risk factors (eg history of fracture, advanced age, comorbidities, etc) that are present, the greater the risk of fracture.

Monitoring

Aim of monitoring is to increase adherence to therapy and to verify response to therapy

Bone Mineral Density (BMD) Measurement

  • Recommended every 1-2 years after initiation of therapy until stable findings and every 2 years thereafter depending on the clinical outcome
  • Central dual energy X-ray absorptiometry (DXA) of the spine or hip is the gold standard for serial BMD assessment
    • Should be done every 2 years
    • If spine, hip or both cannot be assessed, 33% radius site can be used 
  • Patient follow-up ideally should be done within the same facility using the same machine 
  • Age-, disease- and treatment-related BMD changes can be monitored using quantitative computed tomography (QCT) measurement of trabecular BMD 

Bone Turnover Markers

  • Bone resorption markers may be measured before starting therapy and 3 or 6 months after starting treatment
  • Bone formation markers may be measured before starting therapy and 6 months later
  • High levels of bone resorption markers are associated with an increased risk of osteoporotic fractures
    • Resorption markers may be used for assessing fracture risk in selected patients when BMD and clinical risk factors are not sufficient to make treatment decisions

Vertebral Imaging

  • Repeat vertebral imaging is indicated for patients with the following:
    • Documented height loss
    • Presence of vertebral pain
    • Changes in posture
    • Chest X-ray abnormalities
    • Due for reevaluation of treatment with possible withdrawal of therapy
    • Presence of vertebral fracture during off-treatment interval
Reassessment of Postmenopausal Women on Long-Term Bisphosphonate Therapy 
  • Postmenopausal women who have been taking oral bisphosphonates for >5 years or IV bisphosphonates for >3 years should be reassessed for presence of fractures prior to initiation and during therapy
    • Bisphosphonate therapy can be continued beyond 3-5 years in patients ≥75 years old, on high-dose oral glucocorticoid treatment, with prior history of hip or vertebral fracture, or who sustained a low-trauma fracture during therapy
  • If fractures occurred, treatment with bisphosphonates may be continued or may consider the use of other agents
  • If fracture-free, assess BMD T-score or fracture risk
    • If with hip BMD T-score of <-2.5 or with high fracture risk, consider continuing bisphosphonate therapy or may change into other alternative agents
    • If with normal bone mass and still no fractures, may consider withholding treatment and advise patient to follow up for fracture risk assessment every 1.5-3 years

Specialist Referral

  • Consider a referral to a specialist when: 
    • Fragility fractures are experienced
    • A non-major trauma fracture is sustained by a patient with normal BMD 
    • Continued bone loss or recurrent fractures happens in a patient on therapy but has no clear causes of bone loss that are treatable
    • Osteoporosis has uncommon features, is severe, or rare secondary conditions are present, eg hyperparathyroidism, increased prolactin
    • A condition is present that makes management difficult, eg chronic kidney disease, malabsorption
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Tristan Manalac, 06 Oct 2017
In women with polycystic ovary syndrome (PCOS), combined oral contraceptive (COC) with spironolactone is more effective than metformin in reducing symptoms while showing a similar safety profile, according to a new randomized clinical trial (RCT).